Nyrada (ASX:NYR) received approval from the Human Research Ethics Committee to start its first-in-human phase 1a clinical trial evaluating the safety, tolerability, and pharmacokinetics of drug candidate NYR-BI03, according to a Friday filing with the Australian bourse.
NYR-BI03 is a treatment that has the potential to protect both brain and heart tissue.
The double-blind, randomized, placebo-controlled study will administer either NYR-BI03 or placebo to five groups of eight healthy volunteers, with six active and two placebo participants per group, the filing said.
The first dosing is expected to begin by the end of March, according to the filing.
Nyrada's shares were up 5% in afternoon trade Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.